Brands, Medical Use, Clinical Data
Drug Category
- Coagulants
- Thrombotic Agents
Dosage Forms
- Solution (IV injection)
- Solution (IV infusion)
- Tablet
- Powder for solution
Brands / Synonyms
Coagulation factor VII precursor; Eptacog alfa; Novoseven; NovoSeven (Novo Nordisk)
; Proconvertin; Serum prothrombin conversion accelerator; SPCA
Description
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.1 NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indications
For treatment of hemorrhagic complications in hemophilia A and B
Pharmacology
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of Action
NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Not Available
Contraindications
Not Available
Drug Interactions
Not Available
|
